Open main menu

Psychiatrienet β

Combining-Topiramate-Ziprasidone

Revision as of 13:55, 15 June 2010 by Musys (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Topiramate
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX11
PubChem 5284627
PubMed Topiramate
Drugs.com topiramate
Kompas (Dutch) Topiramate
Wikipedia Topiramate
Ziprasidone
Type Antipsychotic
Group Atypical AP
Other use Moodstabilizer
links
Medscape Ziprasidone
PubChem 60854
PubMed Ziprasidone
Wikipedia Ziprasidone

Adding ziprasidone to topiramate.

Infobord.png General information
  • Topiramate induces CYP3A4 and is an inhibitor of CYP2C19.
  • Ziprasidone is metabolized by CYP1A2 (minor) and CYP3A4.
  • Dose adaptation will be recommended for this combination.
  • This combination of drugs may have possible synergistic effects. However, this combination will also have additive side effects.
Eenrichtingbord.png Start ziprasidone
  • Start ziprasidone according general dosing advice.
Letopbord.png Cave
  • Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity. [2]


The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.